Status:
COMPLETED
IM Neostigmine for Accelerating Bladder Emptying After CS by Spinal Anesthesia
Lead Sponsor:
Mansoura University
Conditions:
Cesarean Section Complications
Eligibility:
FEMALE
20-35 years
Phase:
PHASE4
Brief Summary
The aim of this study is to assess the efficacy of IM neostigmine (0.5 mg) for acceleration of bladder evacuation and prevention of postoperative urine retention following cesarean delivery carried ou...
Detailed Description
Following cesarean delivery, women will receive either 0.5 mg IM neostigmine (study group) or IM NaCl 0.9% (control group). Bladder ultrasonography will be done every hour until spontaneous voiding oc...
Eligibility Criteria
Inclusion
- Pregnant women undergoing elective cesarean deliver under spinal anesthesia.
Exclusion
- The age of the patient is more than 35 years of less than 20 years.
- The body mass index of the patient is more than 35 kg/m2 or her height is more than 180 cm or less than 150 cm.
- Multiple gestation.
- The patient is in active labor.
- Vaginal bleeding, placenta previa or abruption of the placenta.
- Presence of fetal distress.
- Urinary symptoms.
- Medical disorders co-existing with or complicating pregnancy.
- Contraindications for or history of adverse reaction of Neostigmine.
- Contraindication for spinal anesthesia.
- Refusal of the patient to receive spinal anesthesia.
- Intraoperative significant hemorrhage.
- Duration of the operation is more than one hour.
- Occurrence of postoperative complications as eclampsia.
Key Trial Info
Start Date :
August 5 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 26 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04364607
Start Date
August 5 2020
End Date
October 26 2021
Last Update
June 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Hospital
Al Mansurah, Dakahlia Governorate, Egypt, 35111